Today the UK government has finally activated Article 50 of the Lisbon Treaty, officially declaring what had been decided nine months ago: they are leaving the European Union for good, by April 2019 at the latest – deal or no deal.
That the European Medicines Agency would have to move from its Canary Wharf offices in London to the Continent had been obvious as soon as the Brexit vote was announ...
Blog
Drug Repurposing Patent Applications Discussed in Upcoming ASSAY Special Issue
Winter is coming…. And that means that ASSAY and Drug Development Technologies will publish another special issue on drug repurposing. Here are the highlights of the PCT patent applications from Q2 and Q3/2016 that will be discussed.
X-Ray Contrast Agents for Ebola (WO/2016/054658, 3e Therapeutics Corp.)
A Heart Failure Drug for Myopathies and Respiratory ALS Complications (WO/2016/059287,...
Presentation at the B·Debate Conference on Drug Repurposing for Rare Diseases
H.M. Pharma Consultancy will present at the·B·Debate conference, Drug Repurposing for Rare Diseases. The Cure for the 21st Century, to be held in Barcelona on November 17 and 18, 2016. This event, jointly organized by Barcelona's innovative health ecosystem, biocat and "la Caixa" Foundation, with Barcelona Science Park (PCB) and Hospital Sant Joan de Déu (HSJD), offers an interdisciplinary forum w...
Selected drug repurposing patent applications published in Q1/2016
This is a selection of PCT patent applications published during the first three months of 2016 that claim new uses for known drugs, and are reviewed in ASSAY and Drug Development Technologies‘ 2016 summer special edition on drug repurposing. This follows up on our blogpost of June 23 where we summarized the patent applications of Q4/2015, also to be published in this issue of ASSAY. – Do not miss ...
Jump the Channel, UK Life Science Companies
Imagine that you are a director of a company. One day you hear one of your employees stating loud and clear, with much feeling: „I have decided to quit!“
But the next day, in Human Resources, when the person is handed his or her papers, eyes and mouth assume the „Big O“ shape: „But I have not resigned! All I had said is that I have decided to quit! A person can make a decision and tell everybod...
Selected drug repurposing patent applications published in Q4/2015
This is a selection of patent applications from Q4/2015 that claim new uses for known drugs, and are reviewed in ASSAY and Drug Development Technologies‘ summer special edition on drug repurposing. Note that this is only about a third of what was actually published in the quarter; activity has been constantly rising in this field of patenting. Q1/2016 to follow soon.
WO/2015/147411 ( Dong-A Uni...
H.M. Pharma Consultancy teams with Excelra for drug repurposing services in Europe
We have signed a collaboration agreement with Excelra Knowledge Solutions Pvt Ltd. of Hyderabad (India) that expands the scope of our drug repurposing offers.
Original press release: http://www.excelra.com/excelra-expands-its-drug-repurposing.php
Excelra expands its Drug Repurposing solutions outreach in Europe through collaboration with H.M. Pharma Consultancy
-- Aims at jointly developi...
Presentation at the Alzheimer Drug Discovery Foundation’s European Didactic Conference
H.M. Pharma Consultancy will present at the 1st European Drug Discovery for Neurodegeneration Conference, to be held in Budapest (Hungary) from May 15-17, 2016. This is an educational course on translational CNS drug research which is based on the Alzheimer Drug Discovery Foundation’s annual US-based Drug Discovery for Neurodegeneration conference.
We will be tweeting from the conference under th...
Dementia Therapy Badly Needs Big Data and Drug Repurposing
Last Saturday (April 30, 2016) I had the honor to present at an educational session for Austrian neuropsychiatry practitioners who care for dementia patients. Somewhat contrary to the general tone of the event, which was dedicated to the challenges of daily practice and their state-of-the-art therapy, my talk rather was about the developments that are about to change the future of said daily routi...
BIA 10-2474: Beyond the Finger Pointing and Speculation, Many Questions
The tragedy that happened during a Phase I first-time-in-man trial in France a few days ago has received widespread attention in the media, as had to be expected when you have five trial participants hospitalized with neurological symptoms of varying degrees, and one dead. It has also highlighted how the interaction between mainstream media, the so-called social media, and members of the scientifi...